Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial

American Heart Journal

Volumn 135, Issue 1, 1998, Pages 29-37

  Tracy, R P ^a   Kleiman, N S ^a   Thompson, B ^a   Cannon, C P ^a   Bovill, E G ^a   Brown, R G ^a   Collen, D ^a   Mahan, E ^a   Mann, K G ^a   Rogers, W J ^a   Sopko, G ^a   Stump, D C ^a   Williams, D O ^a   Zaret, B I ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; HEPARIN; PLASMIN; PLASMINOGEN; STREPTOKINASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART VENTRICULOGRAPHY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESTENOSIS; THROMBOCYTE AGGREGATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031881588     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70339-4     Document Type: Article

References (29)

1. J Gore M Sloan T Price A Young-Randall E Bovill D Collen Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis In Myocardial Infarction study: Thrombolysis In Myocardial Infarction, phase II, pilot and clinical trial Circulation 83 1991 448 459
2. E Bovill M Terrin D Stump A Berke M Frederick D Collen Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI), phase II trial Ann Intern Med 115 1991 256 265
3. J Hsia W Hamilton N Kleiman R Roberts B Chaitman A Ross A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction N Engl J Med 323 1990 1433 1437
4. D de Bono M Simoons J Tijssen A Arnold A Betriu C Burgersdijk Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double-blind European Cooperative Study Group trial Br Heart J 67 1992 122 128
5. M Prins J. Hirsh Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction Am J Cardiol 67 1991 3A 11A
6. R Tracy K Mann E. Bovill Mechanisms of thrombolysis M Ezekowitz Cardiac sources of systemic embolization. 1994 Marcel Dekker New York 55 70
7. C Lee K. Mann Activation/inactivation of human factor V by plasmin Blood 73 1989 185 190
8. M Omar K. Mann Inactivation of factor Va by plasmin J Biol Chem 262 1987 9750 9755
9. R Tracy N Kleiman B Thompson E Bovill E Braunwald B Brown Relationship of coagulation parameters to patency at 18-48 hours in the Thrombolysis in Myocardial Infarction phase II trial [abstract] Clin Res 39 1991 239A
10. C Granger J Hirsh R Califf J Col H White A Betriu Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 93 1996 870 878
11. The TIMI Research Group Immediate vs. delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction JAMA 260 1988 2849 2858
12. The TIMI Study Group Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction N Engl J Med 320 1989 618 627
13. The TIMI Operations Committee E Braunwald G Knatterud E Passamani T Robertson R. Solomon Update from the Thrombolysis in Myocardial Infarction Trial [letter] J Am Coll Cardiol 10 1987 970
14. The TIMI Research Group The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings N Engl J Med 312 1985 932 936
15. B Zaret F Wackers M Terrin R Ross M Weiss J Slater Assessment of global and regional left ventricular performance at rest and during exercise after thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II Study Am J Cardiol 69 1992 1 9
16. B Zaret F Wackers M Terrin S Forman D Williams G Knatterud Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction: results of Thrombolysis In Myocardial Infarction (TIM1) phase II study J Am Coll Cardiol 26 1995 73 79
17. R Tracy E Bovill D Stump T Lin T Gomol D Collen Reduction of in vitro artifact during blood collection in TIMI II [abstract] Blood 78 suppl 1 1988 376
18. J Hsia N Kleiman F Aguirre B Chaitman R Roberts A Ross Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency J Am Coll Cardiol 20 1992 31 35
19. J Arnout M Simoons D de Bono H Rapold D Collen M. Verstraete Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA) J Am Coll Cardiol 20 1992 513 519
20. S Bleich T Nichols R Schumacher D Cooke D Tate S. Teichman Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction Am J Cardiol 66 1990 1412 1417
21. E Topol B George D Kereiakes D Stump R Candela C Abbottsmith A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction Circulation 79 1989 281 286
22. D Rubin R Tracy K Mann P. Tracy Western blotting of human factors V and Va in patients with disseminated intravascular coagulation (DIC) and in patients with exercise-induced angina pectoris [abstract] Circulation 74 suppl II 1986 II411
23. A Rao C Pratt A Berke A Jaffe I Ockene T Schreiber Thrombolysis In Myocardial Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase [abstract] J Am Coll Cardiol 11 1988 1 11
24. D Stump E Topol A Chen A Hopkins D. Collen Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator Thromb Haemost 59 1988 133 137
25. C Grines E Topol W O'Neill B George D Kereiakes H Phillips Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction Circulation 91 1995 298 303
26. D Zahger B Cercek C Cannon M Jordan V Davis E Braunwald How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial) Am J Cardiol 75 1995 232 236
27. S Torr D Machowiak S Fujii B Sobel “Plasminogen steal” and clot lysis J Am Coll Cardiol 19 1992 1085 1090
28. R Califf E Topol B George J Boswick C Abbottsmith K Sigmon Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction Am J Med 85 1988 353 359
29. D Stump R Califf E Topol K Sigmon D Thornton R Masek Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction Circulation 80 1989 1222 1230